Endometriosis Drugs Market Will Reach $1.92bn In 2020, According To New Visiongain Data

12 September 2018
Pharma

A new report by visiongain forecasts that the endometriosis drugs market will achieve sales of $1.92 billion worldwide in 2020. That pharma market will experience revenue growth from 2016 to 2026, adapting to driving and restraining forces – changes, opportunities and threats. That revenue prediction and others appear in Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of that Expanding Market for Treating a Prevalent Women’s Reproductive System Disorder.

Visiongain published that report in February 2016. That company is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand potentials of industries and markets in healthcare and other fields.

10% of women worldwide have endometriosis, giving high, rising demand for medicines. In 2014 Lupron was the leading product for revenue generation in the endometriosis drugs market, accounting for 8.9% of that world market. Visanne became the second-highest selling drug in the endometriosis medicines market. The top five endometriosis drugs accounted for 30.2% of the total market. In 2014 and 2015, the US formed the leading national market for endometriosis therapies. Japan held second place for revenue generation from endometriosis-treating drugs. Visiongain’s study predicts that India will form the fastest growing emerging market there from 2016 to 2026. In 2014 AbbVie was the leading company, in a market holding some of the world’s largest pharmaceutical developers, producers and marketers.

From 2016 endometriosis treatment will face challenges through healthcare reforms and budgetary restrictions, but will benefit from increasing awareness of that women’s disease. That industry will also benefit from the launch of new products, from strong R&D in 2016. Success of that market will depend on awareness programmes and increasing demand from women for treatment, with rising disease incidence and improving diagnosis methods. Those developments give opportunity for healthcare companies to gain success by launching novel medicines and medical devices to suit patients’ needs worldwide.

Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “Endometriosis is one of the most widespread chronic conditions in women. Current diagnostic and treatment strategies possess limitations, reportedly causing side effects and inconvenience to patients. Many pharmaceutical companies are developing novel medicines with different therapeutic targets for treating endometriosis. The need for advances in medical technologies for better diagnoses and treatment for endometriosis expands, giving opportunities for companies and healthcare providers. And better treatment of endometriosis depends on greater understanding of the disease in medical science and the pharma industry, as well as more awareness programmes by healthcare providers.”

That therapeutic segment holds promising R&D. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, the study notes. There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients.

Visiongain’s new report predicts trends and revenues of the endometriosis drugs market from 2016 to 2026, also giving recent sales results. That analysis shows revenue forecasts at overall world, product and national level to 2026. It also discusses research and development and shows an interview with an authority on that prevalent women’s reproductive system disease.

Revenue predictions to 2026 appear for these five brands, with discussions and supporting data:

• Lupron
• Eligard
• Zoladex
• Depo-Provera
• Visanne.

At world level that study discusses and forecasts endometriosis medicine revenues overall and at national level from 2016 to 2026, covering these 11 leading countries:

• US
• Japan
• Germany, France, Italy, Spain, UK (EU5)
• China, Brazil, India, Russia (BRIC).

Visiongain’s new investigation also gives qualitative analysis of the endometriosis medicines market, including R&D discussions, SWOT analysis and PEST assessment. It assesses leading pharmaceutical companies, too, including these organisations:

• AbbVie
• Pfizer
• Bayer HealthCare
• AstraZeneca
• Astellas
• Takeda.

Endometriosis Drug Forecasts and R&D 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics, biotechnologies and outsourced services in drug development, sales and manufacturing.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever